We are live on ! Find out more
RAPT icon

RAPT Therapeutics

Delisted

RAPT was delisted on the 2nd of March, 2026.

109 hedge funds and large institutions have $847M invested in RAPT Therapeutics in 2021 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 35 increasing their positions, 23 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

380% more capital inflows, than outflows

Capital inflows: $164M | Capital outflows: $34.3M

344% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 9

52% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 23

40% more funds holding

Funds holding: 78 → 109 (+31)

33% more funds holding in top 10

Funds holding in top 10: 9 → 12 (+3)

5.91% more ownership

Funds ownership: 84.85% → 90.76% (+5.9%)

2% less call options, than puts

Call options by funds: $53.3M | Put options by funds: $54.3M

Holders
109
Holders Change
+31
Holders Change %
+39.74%
% of All Funds
1.89%
Holding in Top 10
12
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+33.33%
% of All Funds
0.21%
New
40
Increased
35
Reduced
23
Closed
9
Calls
$53.3​M
Puts
$54.3​M
Net Calls
-⁠$1.02​M
Net Calls Change
-⁠$14.2​M

RAPT Hedge Fund Activity: Q2 2021 in Review

109 of the 5,771 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q2 2021, worth a combined $847M — up 81% from $468M a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new RAPT positions and 9 closed out — a net gain of 31 holders — while 35 added to existing stakes and 23 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $23.7M. The largest seller was KPCB XV Associates, cutting an estimated $15.2M.

  • 109 institutional investors held RAPT Therapeutics (RAPT) as of Q2 2021, up from 78 in Q1 2021.
  • Funds reported $847M of RAPT Therapeutics stock for Q2 2021, up 81% quarter-over-quarter.
  • 40 funds opened new RAPT Therapeutics positions in Q2 2021 and 9 closed out, a net change of +31 holders.
  • The largest RAPT Therapeutics buyer in Q2 2021 was T. Rowe Price Associates, an estimated $23.7M added.
  • The largest RAPT Therapeutics seller in Q2 2021 was KPCB XV Associates, an estimated $15.2M sold.

Based on aggregated 13F filings for Q2 2021.